Literature DB >> 29443616

Adapting Practice in the Face of New Data.

Christopher Stokoe.   

Abstract

Oncologists are often faced with new information on tests, therapies, and treatment regimens. Determining how to incorporate that data into practice patterns is not easy. Regardless of what motivates you to make a change in practice, the explosion of new oncology data demands that you continually reevaluate how you practice.

Year:  2009        PMID： 29443616      PMCID： PMC2790637          DOI： 10.1200/JOP.0922501

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


  8 in total

1.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Authors:  D J Slamon; B Leyland-Jones; S Shak; H Fuchs; V Paton; A Bajamonde; T Fleming; W Eiermann; J Wolter; M Pegram; J Baselga; L Norton
Journal:  N Engl J Med       Date:  2001-03-15       Impact factor: 91.245

2.  ASCO Provisional Clinical Opinion: KRAS, Cetuximab, and Panitumumab-Clinical Implications in Colorectal Cancer.

Authors:  Roscoe F Morton; Elizabeth H Hammond
Journal:  J Oncol Pract       Date:  2009-03       Impact factor: 3.840

3.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Authors:  Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

4.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

Authors:  Edward H Romond; Edith A Perez; John Bryant; Vera J Suman; Charles E Geyer; Nancy E Davidson; Elizabeth Tan-Chiu; Silvana Martino; Soonmyung Paik; Peter A Kaufman; Sandra M Swain; Thomas M Pisansky; Louis Fehrenbacher; Leila A Kutteh; Victor G Vogel; Daniel W Visscher; Greg Yothers; Robert B Jenkins; Ann M Brown; Shaker R Dakhil; Eleftherios P Mamounas; Wilma L Lingle; Pamela M Klein; James N Ingle; Norman Wolmark
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

5.  FDA report: eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuria.

Authors:  Andrew Dmytrijuk; Kathy Robie-Suh; Martin H Cohen; Dwaine Rieves; Karen Weiss; Richard Pazdur
Journal:  Oncologist       Date:  2008-09-10

6.  Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria.

Authors:  Peter Hillmen; Petra Muus; Ulrich Dührsen; Antonio M Risitano; Jörg Schubert; Lucio Luzzatto; Hubert Schrezenmeier; Jeffrey Szer; Robert A Brodsky; Anita Hill; Gerard Socié; Monica Bessler; Scott A Rollins; Leonard Bell; Russell P Rother; Neal S Young
Journal:  Blood       Date:  2007-08-16       Impact factor: 22.113

7.  Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

Authors:  Rafael G Amado; Michael Wolf; Marc Peeters; Eric Van Cutsem; Salvatore Siena; Daniel J Freeman; Todd Juan; Robert Sikorski; Sid Suggs; Robert Radinsky; Scott D Patterson; David D Chang
Journal:  J Clin Oncol       Date:  2008-03-03       Impact factor: 44.544

8.  Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria.

Authors:  Robert A Brodsky; Neal S Young; Elisabetta Antonioli; Antonio M Risitano; Hubert Schrezenmeier; Jörg Schubert; Anna Gaya; Luke Coyle; Carlos de Castro; Chieh-Lin Fu; Jaroslaw P Maciejewski; Monica Bessler; Henk-André Kroon; Russell P Rother; Peter Hillmen
Journal:  Blood       Date:  2007-11-30       Impact factor: 22.113
  8 in total
  1 in total

Review 1.  Erythropoietin or darbepoetin for patients with cancer.

Authors:  Thomy Tonia; Annette Mettler; Nadège Robert; Guido Schwarzer; Jerome Seidenfeld; Olaf Weingart; Chris Hyde; Andreas Engert; Julia Bohlius
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.